AOD-9604 Cycles Explained: Where the Evidence Stops

AOD-9604 at a glance:

• Drug class: Metabolic / longevity research peptide
• Route: subcutaneous injection in research
• Typical frequency: no established human regimen
• Half-life: typically short systemically

AOD-9604 cycling discussions trace to bodybuilding-era practice and receptor-desensitization theory. The evidence base supporting any specific cycle is thin to nonexistent.

What "Cycle" Means in Peptide Discussions

In research-peptide and GHS communities, a "cycle" usually refers to a defined period of administration (often 8-12 weeks) followed by a break. The rationale draws on receptor desensitization theory and historical bodybuilding practice.

For AOD-9604: no formal cycling protocol has been studied in human RCTs. Online protocols are extrapolations, not evidence-based recommendations.

Published Research Dosing

No FDA-approved human dosing.

When peptides are studied in research, the doses come from animal-to-human translation, prior pharmacokinetic data, and trial designs that can't be assumed to apply to individual self-administration.

What Researchers Actually Do

In the published research literature on AOD-9604:

• Doses are typically expressed in mcg/kg or fixed mg amounts
• Administration routes match what was tested for safety
• Duration is bounded by the trial protocol (often 8-12 weeks)
• Outcome measurement is structured and pre-specified

These are not personal protocols; they're trial designs.

Why We Don't Publish Self-Administration Protocols

Three reasons:

1. Compound purity and identity are not verifiable for material from grey-market sources
2. Individual response to non-FDA-approved compounds is not characterized at the population level
3. Liability and safety realities make specific instructions inappropriate for an informational site

For AOD-9604 specifically, human safety data is essentially absent.

What to Do Instead

If you're researching AOD-9604 because of a specific health goal, the more productive path is usually:

• Identify the underlying issue (musculoskeletal, metabolic, etc.)
• Look at FDA-approved options that address it
• Talk to a clinician with relevant expertise
• Consider research-peptide options only as a last resort, with clear understanding of unknowns

Risks to Understand

• unknown long-term effects

These are compound to the risks of unregulated supply (purity, contamination, dosing accuracy).

Bottom Line

We don't publish AOD-9604 cycling protocols because the evidence doesn't support specific recommendations. The honest answer is: research dosing exists, but it's not personal advice.

Frequently Asked Questions

Related Reading

• AOD-9604 101: A Plain-English Guide for 2026
• AOD-9604 Side Effects Decoded: What's Normal vs. What Isn't
• Real AOD-9604 Results: What 6 and 12 Months Actually Look Like
• AOD-9604 Price Decoded: Insurance, Coupons, and Cash-Pay Options
• NAD+ 101: A Plain-English Guide for 2026
• NAD+ Side Effects Decoded: What's Normal vs. What Isn't

Sources

• Birk AV et al. The Mitochondrial-Targeted Peptide SS-31 Selectively Improves Mitochondrial Function. JASN 2013;24:1250.
• Lee C et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis. Cell Metabolism 2015;21:443.

This page is informational only and is not medical advice or a recommendation for self-administration of any compound.